Evidence map›Paper›PMID 38135754›Full record

ArticleMolecular psychiatry2024

Validation of plasma protein glycation and oxidation biomarkers for the diagnosis of autism.

Aisha Nasser J M Al-Saei, Wared Nour-Eldine, Kashif Rajpoot, Noman Arshad, Abeer R Al-Shammari, Madeeha Kamal, Ammira Al-Shabeeb Akil, Khalid A Fakhro, Paul J Thornalley, Naila Rabbani

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Aisha Nasser J M Al-SaeiCollege of Medicine, QU Health, Qatar University, PO Box 2713, Doha, Qatar.ORCID 0000-0001-9380-3221
Wared Nour-EldineQatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, PO Box 34110, Doha, Qatar.ORCID 0000-0002-7605-6989
Kashif RajpootUniversity of Birmingham Dubai, Dubai International Academic City, PO Box 341799, Dubai, UAE.
Noman ArshadBIOMISA Laboratory, Department of Computer & Software Engineering, National University of Science & Technology (NUST), Islamabad, Pakistan.ORCID 0009-0004-5119-333X
Abeer R Al-ShammariQatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, PO Box 34110, Doha, Qatar.ORCID 0000-0003-4169-3459
Madeeha KamalCollege of Medicine, QU Health, Qatar University, PO Box 2713, Doha, Qatar.
Ammira Al-Shabeeb AkilPrecision Medicine in Diabetes Prevention Laboratory, Population Genetics, Sidra Medicine, P.O. Box 26999, Doha, Qatar.
Khalid A FakhroDepartment of Genetic Medicine, Weill Cornell Medical College, Doha, P.O. Box 24144, Doha, Qatar.ORCID 0000-0002-3150-1276
Paul J ThornalleyQatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, PO Box 34110, Doha, Qatar.ORCID 0000-0001-7659-443X
Naila RabbaniCollege of Medicine, QU Health, Qatar University, PO Box 2713, Doha, Qatar. n.rabbani@qu.edu.qa.ORCID 0000-0002-5819-2506
Hamad bin Khalifa University · QAQatar Airways (Qatar) · QAQatar University · QANational University of Sciences and Technology · PKUniversity of Dubai · AE

Funding

Qatar University (QU) QUHIG-CMED-2021/22-1
6 · The paper itself

Abstract

Autism Spectrum Disorder (ASD) is a common neurodevelopmental disorder in children. It is currently diagnosed by behaviour-based assessments made by observation and interview. In 2018 we reported a discovery study of a blood biomarker diagnostic test for ASD based on a combination of four plasma protein glycation and oxidation adducts. The test had 88% accuracy in children 5-12 years old. Herein, we present an international multicenter clinical validation study (N = 478) with application of similar biomarkers to a wider age range of 1.5-12 years old children. Three hundred and eleven children with ASD (247 male, 64 female; age 5.2 ± 3.0 years) and 167 children with typical development (94 male, 73 female; 4.9 ± 2.4 years) were recruited for this study at Sidra Medicine and Hamad Medical Corporation hospitals, Qatar, and Hospital Regional Universitario de Málaga, Spain. For subjects 5-12 years old, the diagnostic algorithm with features, advanced glycation endproducts (AGEs)-N

Indexed as

Autism Spectrum DisorderBiomarkersGlycation End Products, AdvancedOxidation-ReductionAutistic DisorderBlood ProteinsChildChild, PreschoolFemaleGlycosylationHumansInfantLysineMaleSensitivity and SpecificityBiomarkersBlood ProteinsGlycation End Products, AdvancedLysineN(6)-carboxymethyllysine

Identifiers

PMID38135754
PMCPMC11153128
OpenAlexW4390106971

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.